イミュニク
Immunic, Inc.
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.80 | $0 | -$31M |
| 2026 Q1 | -1.08 | $0 | -$17M |
| 2025 Q4 | -1.60 | $0 | -$19M |
| 2025 Q3 | -1.32 | $0 | -$20M |
| 2025 Q2 | -2.03 | $0 | -$25M |
| 2025 Q1 | -2.51 | $0 | -$22M |
| 2024 Q4 |
| -2.79 |
| $0 |
| -$23M |
| 2024 Q3 | -2.41 | $0 | -$21M |